AstraZeneca
guidance strong underlying business drives growth well ahead of declines in covid medicines total revenue excluding covid medicines low double digit increase including covid medicines low to mid single digit increase core high single digit to low double digit increase other elements of guidance total revenue from covid medicines expected to decline significantly total revenue from china is expected to return to growth and increase by a low single digit collaboration revenue and other operating income are both expected to increase core operating expenses to increase low to mid single digit core tax rate expected to be between low single digit anticipated for total revenue and core | AstraZeneca
Company
Deck Type
Deck date
February 2023
Slide
13 of 45
Related slides by other companies
Results
August 2023
Results
November 2022
Investor Day
May 2022
Investor Day
November 2022
Other recent decks by AstraZeneca
Results
February 2024
Investor Conference
January 2024
Results
November 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io